Literature DB >> 9550372

Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization.

R B Mendoza1, M J Cantwell, T J Kipps.   

Abstract

Interaction of CD40 with its ligand (CD154) can induce CD40-bearing APCs to express immune stimulatory accessory molecules that facilitate immune recognition. We evaluated whether a plasmid vector encoding CD154 (pCD40L) could influence the immune response to a transgene protein encoded by coinjected plasmid DNA. We found that coinjection of pCD40L in BALB/c mice enhanced the Ab response to beta-galactosidase induced by i.m. or intradermal injection of placZ, a plasmid DNA vector encoding beta-galactosidase. Furthermore, i.m. or intradermal coinjection of pCD40L with placZ enhanced the generation of CTL specific for P815 cells transfected with placZ. This study indicates that pCD40L can serve as a genetic adjuvant capable of augmenting humoral and cellular immune responses to Ags encoded by plasmid DNA expression vectors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9550372

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Masaki Terabe; Rima Koka; Debra D Donaldson; Elaine K Thomas; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

Review 3.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

4.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

6.  Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.

Authors:  Sheryl L Gares; Karl P Fischer; Stephen E Congly; Stacey Lacoste; William R Addison; D Lorne Tyrrell; Klaus S Gutfreund
Journal:  Clin Vaccine Immunol       Date:  2006-08

7.  Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1.

Authors:  A Ihata; S Watabe; S Sasaki; A Shirai; J Fukushima; K Hamajima; J Inoue; K Okuda
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

8.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.

Authors:  S Gurunathan; K R Irvine; C Y Wu; J I Cohen; E Thomas; C Prussin; N P Restifo; R A Seder
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

9.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.

Authors:  Tetsuya Fukuda; Liguang Chen; Tomoyuki Endo; Li Tang; Desheng Lu; Januario E Castro; George F Widhopf; Laura Z Rassenti; Mark J Cantwell; Charles E Prussak; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

10.  Modulation of immune responses to bovine herpesvirus-1 in cattle by immunization with a DNA vaccine encoding glycoprotein D as a fusion protein with bovine CD154.

Authors:  Sharmila Manoj; Philip J Griebel; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.